The invention describes novel nitrosated and / or nitrosylated compounds of the invention, and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and / or nitrosylated compound of the invention, and, optionally, at least one
nitric oxide donor compound and / or at least one therapeutic agent. The invention also provides novel compositions comprising at least one compound of the invention, that is optionally nitrosated and / or nitrosylated, and at least one
nitric oxide donor compound and / or at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for treating cardiovascular diseases, for inhibiting
platelet aggregation and
platelet adhesion caused by the
exposure of blood to a
medical device, for treating
pathological conditions resulting from
abnormal cell proliferation;
transplantation rejections, autoimmune, inflammatory, proliferative, hyperproliferative or vascular diseases; for reducing
scar tissue or for inhibiting wound contraction, particularly the prophylactic and / or
therapeutic treatment of
restenosis by administering at least one compound of the invention that is optionally nitrosated and / or nitrosylated, in combination with
nitric oxide donors that are capable of releasing nitric
oxide or indirectly delivering or transferring nitric
oxide to targeted sites under physiological conditions. The compounds of the invention are preferably estradiol compounds, troglitazone compounds,
tranilast compounds,
retinoic acid compounds, resveratol compounds, myophenolic acid compounds, acid compounds, anthracenone compounds and trapidil compounds.